Computed tomography and positron emission tomography in the assessment of aortic valve disease

Introduction Native and bioprosthetic aortic valve diseases are an increasingly common clinical challenge as a consequence of the ageing demographic and the expansion of new valve technology. In both conditions, there remains substantial scope to broaden our understanding of the pathophysiology, improve diagnostic sensitivity and accuracy, and develop new markers of disease activity with which to measure therapeutic effect. Computed tomography (CT) and positron emission tomography (PET) are non-invasive imaging assessments that combine high resolution anatomical detail with real-time functional information about disease activity, and as such are ideally suited to complement echocardiography in the investigation of native and bioprosthetic aortic valve diseases. Methods Aortic Stenosis Volunteers with aortic stenosis (n=143) across a range of severity underwent echocardiography, CT aortic valve calcium scoring and contrast-enhanced CT angiography. Aortic valve fibrosis and calcification were quantified to produce two novel measures: the fibro-calcific ratio and fibro-calcific burden. From the same study population, a subset of 15 volunteers underwent hybrid 18F-fluoride PET/CT on two separate occasions and we investigated different methods of image analysis to optimise accuracy and reproducibility. Bioprosthetic Valves Explanted degenerated bioprosthetic valves (n=16) were examined ex vivo using histopathology and preclinical 18F-fluoride PET/CT. Patients with bioprosthetic aortic valves (n=78) were then recruited into two cohorts, with and without prosthetic valve dysfunction, and underwent in-vivo contrast-enhanced CT angiography, 18F-fluoride PET, and serial echocardiography over 2 years of follow-up. Results Aortic Stenosis Contrast-enhanced CT calcium volume correlated closely with conventional CT calcium score in the aortic valve (r=0.86, p=<0.001). Fibrosis dominated in mild aortic stenosis while calcification dominated in severe stenosis (fibro-calcific ratio: 1.33 [0.91-2.4]) versus 0.53 [0.35-1.05] respectively; p=0.001). Males exhibited more calcium than fibrosis, with the reverse true for females (fibro-calcific ratio: 0.89 [0.45-1.54] versus 1.49 [0.82-5.74] respectively; p=0.001). The fibro-calcific burden demonstrated the strongest correlation with peak aortic-jet velocity (r=0.71, p<0.001), especially in women (r=0.77, p=0.001) where it outperformed CT calcium score (p=0.027). In our investigation of 18F-fluoride-PET/CT, contrast-enhanced, ECG-gated PET/CT provided superior spatial localisation of 18F-fluoride uptake. Scan-rescan reproducibility was markedly improved using enhanced analysis techniques leading to a reduction in variability from 25% to <10%. Bioprosthetic Valves In degenerated bioprosthetic valves ex vivo, calcification was the most prevalent pathological feature (87%), whilst thrombus (40%) and pannus overgrowth (47%) were other common findings. All valves exhibited 18F-fluoride uptake on PET, with a strong positive correlation between 18F-fluoride uptake and calcium volume (r=0.73, p=0.0031). 18F-Fluoride uptake was highest in regions of leaflet calcification but also localised to regions of organised thrombus, fibrosis and features of matrix degradation on histopathology. In the cohort study of patients with bioprosthetic aortic valves, all those with recognised valve dysfunction exhibited abnormalities on CT and high 18F-fluoride uptake. In the 71 patients without valve dysfunction, 20% had leaflet pathology on CT and 34% had increased 18F-fluoride uptake (target-to-background ratio 1.55 [1.44-1.88]). Patients with increased 18F-fluoride uptake exhibited more rapid deterioration in valve function than those without (annualised change in peak transvalvular velocity: 0.30 [0.13-0.61] versus 0.01 [-0.05-0.16] ms-1/year, p<0.001). 18F-Fluoride uptake correlated with deterioration in all echocardiographic measures of valve function (e.g. change in peak velocity, r=0.72; p<0.001) and, on multivariable analysis, was the only independent predictor of future bioprosthetic dysfunction. Conclusions In both native aortic valve disease and bioprosthetic valve disease, CT and 18F-fluoride PET afford valuable insights into disease mechanisms, inform patient risk stratification and prognosis, and provide biomarkers of disease activity that may be used for the development of future therapeutic interventions

Complementary role of cardiac CT in the assessment of aortic valve replacement dysfunction

Aortic valve replacement is the second most common cardiothoracic procedure in the UK. With an ageing population, there are an increasing number of patients with prosthetic valves that require follow-up. Imaging of prosthetic valves is challenging with conventional echocardiographic techniques making early detection of valve dysfunction or complications difficult. CT has recently emerged as a complementary approach offering excellent spatial resolution and the ability to identify a range of aortic valve replacement complications including structural valve dysfunction, thrombus development, pannus formation and prosthetic valve infective endocarditis. This review discusses each and how CT might be incorporated into a multimodal cardiovascular imaging pathway for the assessment of aortic valve replacements and in guiding clinical management

Contrast-enhanced computed tomography assessment of aortic stenosis

Abstract Objectives Non-contrast CT aortic valve calcium scoring ignores the contribution of valvular fibrosis in aortic stenosis. We assessed aortic valve calcific and non-calcific disease using contrast-enhanced CT. Methods This was a post hoc analysis of 164 patients (median age 71 (IQR 66–77) years, 78% male) with aortic stenosis (41 mild, 89 moderate, 34 severe; 7% bicuspid) who underwent echocardiography and contrast-enhanced CT as part of imaging studies. Calcific and non-calcific (fibrosis) valve tissue volumes were quantified and indexed to annulus area, using Hounsfield unit thresholds calibrated against blood pool radiodensity. The fibrocalcific ratio assessed the relative contributions of valve fibrosis and calcification. The fibrocalcific volume (sum of indexed non-calcific and calcific volumes) was compared with aortic valve peak velocity and, in a subgroup, histology and valve weight. Results Contrast-enhanced CT calcium volumes correlated with CT calcium score (r=0.80, p<0.001) and peak aortic jet velocity (r=0.55, p<0.001). The fibrocalcific ratio decreased with increasing aortic stenosis severity (mild: 1.29 (0.98–2.38), moderate: 0.87 (1.48–1.72), severe: 0.47 (0.33–0.78), p<0.001) while the fibrocalcific volume increased (mild: 109 (75–150), moderate: 191 (117–253), severe: 274 (213–344) mm3/cm2). Fibrocalcific volume correlated with ex vivo valve weight (r=0.72, p<0.001). Compared with the Agatston score, fibrocalcific volume demonstrated a better correlation with peak aortic jet velocity (r=0.59 and r=0.67, respectively), particularly in females (r=0.38 and r=0.72, respectively). Conclusions Contrast-enhanced CT assessment of aortic valve calcific and non-calcific volumes correlates with aortic stenosis severity and may be preferable to non-contrast CT when fibrosis is a significant contributor to valve obstruction

Serum Lipoprotein(a) and Bioprosthetic Aortic Valve Degeneration

AIMS: Bioprosthetic aortic valve degeneration demonstrates pathological similarities to aortic stenosis. Lipoprotein(a) [Lp(a)] is a well-recognized risk factor for incident aortic stenosis and disease progression. The aim of this study is to investigate whether serum Lp(a) concentrations are associated with bioprosthetic aortic valve degeneration. METHODS AND RESULTS: In a post hoc analysis of a prospective multimodality imaging study (NCT02304276), serum Lp(a) concentrations, echocardiography, contrast-enhanced computed tomography (CT) angiography, and 18F-sodium fluoride (18F-NaF) positron emission tomography (PET) were assessed in patients with bioprosthetic aortic valves. Patients were also followed up for 2 years with serial echocardiography. Serum Lp(a) concentrations [median 19.9 (8.4-76.4) mg/dL] were available in 97 participants (mean age 75 ± 7 years, 54% men). There were no baseline differences across the tertiles of serum Lp(a) concentrations for disease severity assessed by echocardiography [median peak aortic valve velocity: highest tertile 2.5 (2.3-2.9) m/s vs. lower tertiles 2.7 (2.4-3.0) m/s, P = 0.204], or valve degeneration on CT angiography (highest tertile n = 8 vs. lower tertiles n = 12, P = 0.552) and 18F-NaF PET (median tissue-to-background ratio: highest tertile 1.13 (1.05-1.41) vs. lower tertiles 1.17 (1.06-1.53), P = 0.889]. After 2 years of follow-up, there were no differences in annualized change in bioprosthetic hemodynamic progression [change in peak aortic valve velocity: highest tertile [0.0 (-0.1-0.2) m/s/year vs. lower tertiles 0.1 (0.0-0.2) m/s/year, P = 0.528] or the development of structural valve degeneration. CONCLUSION: Serum lipoprotein(a) concentrations do not appear to be a major determinant or mediator of bioprosthetic aortic valve degeneration

Effect of denosumab or alendronic acid on the progression of aortic stenosis: A double-blind randomized controlled trial

Background: Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic differentiation of valvular interstitial cells are important contributory mechanisms. We aimed to establish whether inhibition of these pathways with denosumab or alendronic acid could reduce disease progression in aortic stenosis. Methods: In a single-center, parallel group, double-blind randomized controlled trial, patients >50 years of age with calcific aortic stenosis (peak aortic jet velocity >2.5 m/s) were randomized 2:1:2:1 to denosumab (60 mg every 6 months), placebo injection, alendronic acid (70 mg once weekly), or placebo capsule. Participants underwent serial assessments with Doppler echocardiography, computed tomography aortic valve calcium scoring, and 18F-sodium fluoride positron emission tomography and computed tomography. The primary end point was the calculated 24-month change in aortic valve calcium score. Results: A total of 150 patients (mean age, 72±8 years; 21% women) with calcific aortic stenosis (peak aortic jet velocity, 3.36 m/s [2.93-3.82 m/s]; aortic valve calcium score, 1152 AU [655-2065 AU]) were randomized and received the allocated trial intervention: denosumab (n=49), alendronic acid (n=51), and placebo (injection n=25, capsule n=25; pooled for analysis). Serum C-terminal telopeptide, a measure of bone turnover, halved from baseline to 6 months with denosumab (0.23 [0.18-0.33 µg/L] to 0.11 µg/L [0.08-0.17 µg/L]) and alendronic acid (0.20 [0.14-0.28 µg/L] to 0.09 µg/L [0.08-0.13 µg/L]) but was unchanged with placebo (0.23 [0.17-0.30 µg/L] to 0.26 µg/L [0.16-0.31 µg/L]). There were no differences in 24-month change in aortic valve calcium score between denosumab and placebo (343 [198-804 AU] versus 354 AU [76-675 AU]; P=0.41) or alendronic acid and placebo (326 [138-813 AU] versus 354 AU [76-675 AU]; P=0.49). Similarly, there were no differences in change in peak aortic jet velocity or 18F-sodium fluoride aortic valve uptake. Conclusions: Neither denosumab nor alendronic acid affected progression of aortic valve calcification in patients with calcific aortic stenosis. Alternative pathways and mechanisms need to be explored to identify disease-modifying therapies for the growing population of patients with this potentially fatal condition. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02132026

Early experience of intravascular lithotripsy in unprotected calcified left main coronary artery disease

BackgroundTreatment of unprotected severely calcified left main coronary artery (LMCA) disease is a complex interventional procedure. Intravascular lithotripsy (IVL) and rotational atherectomy (RA) are safe and effective methods of treating coronary calcification in the non-LMCA setting. This retrospective analysis assessed the feasibility of IVL versus RA in unprotected LMCA disease.MethodsWe analyzed IVL and RA procedures performed at a large tertiary hospital in the Northeast of England from January 1, 2019 to April 31, 2022. Major safety and efficacy endpoints were procedural and angiographic success, defined by stent delivery with 0.05). In 3 LMCA IVL and 3 LMCA RA cases arrhythmias and cardiac tamponade complicated the procedures respectively. At 1 year, MACE occurred in 10/44 (22.7 %) LMCA IVL, 16/81 (19.8 %) LMCA RA and 25/117 (21.4 %) cases (p > 0.05).ConclusionIn our single center retrospective analysis, IVL is feasible in unprotected calcified LMCA as a second-line and third-line adjuvant calcium modification technique. Its use in unprotected calcified LMCA disease should be formalized with the undertaking of large randomized controlled trials

Microvascular Obstruction in Acute Myocardial Infarction, a Potential Therapeutic Target

Microvascular obstruction (MVO) is a recognised phenomenon following mechanical reperfusion in patients presenting with ST-segment elevation myocardial infarction (STEMI). Invasive and non-invasive modalities to detect and measure the extent of MVO vary in their accuracy, suggesting that this phenomenon may reflect a spectrum of pathophysiological changes at the level of coronary microcirculation. The importance of detecting MVO lies in the observation that its presence adds incremental risk to patients following STEMI treatment. This increased risk is associated with adverse cardiac remodelling seen on cardiac imaging, increased infarct size, and worse patient outcomes. This review provides an outline of the pathophysiology, clinical implications, and prognosis of MVO in STEMI. It describes historic and novel pharmacological and non-pharmacological therapies to address this phenomenon in conjunction with primary PCI